EA200970420A1 - APPLICATIONS OF MTKI 1 FOR THE TREATMENT OR PREVENTION OF BONE CANCER - Google Patents

APPLICATIONS OF MTKI 1 FOR THE TREATMENT OR PREVENTION OF BONE CANCER

Info

Publication number
EA200970420A1
EA200970420A1 EA200970420A EA200970420A EA200970420A1 EA 200970420 A1 EA200970420 A1 EA 200970420A1 EA 200970420 A EA200970420 A EA 200970420A EA 200970420 A EA200970420 A EA 200970420A EA 200970420 A1 EA200970420 A1 EA 200970420A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bone
bone cancer
prevention
treatment
cancer
Prior art date
Application number
EA200970420A
Other languages
Russian (ru)
Inventor
Тимоти Пьетро Сурен Перера
Мишель Мари Франсуа Жанико
Тео Франс Мерт
Эдди Жан Эдгар Фрейн
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA200970420A1 publication Critical patent/EA200970420A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Настоящее изобретение связано с обнаружением того факта, что макроциклическое производное хиназолина 17-бром-8,9,10,11,12,13,14,19-октагидро-20-метокси-13-метил-4,6-этандиилиденпиримидо[4,5-b][6,1,12]бензоксадиазациклопентадецин, описанное как соединение 22 в РСТ-публикации WO 2004/105765, пригодно для изготовления лекарственного средства для лечения или предупреждения раковых заболеваний кости, и со способами уничтожения клеток рака кости, включая остеосаркомы, хондросаркомы, миеломную болезнь кости и остеолитические метастазы в кости из других первичных очагов. Согласно этому настоящее изобретение предоставляет способы лечения, предупреждения, задержки или уменьшения тяжести рака кости или предупреждения и лечения потери костной массы, связанной с метастазами рака.The present invention is associated with the discovery of the fact that the macrocyclic derivative of quinazoline 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-4,6-ethanediylidene pyrimido [4, 5-b] [6,1,12] benzoxadiazacyclopentadecin, described as compound 22 in PCT publication WO 2004/105765, is suitable for the manufacture of a medicament for the treatment or prevention of bone cancer, and with methods for killing bone cancer cells, including osteosarcomas, chondrosarcoma, bone myeloma and osteolytic bone metastases from other primary och Gov. Accordingly, the present invention provides methods for treating, preventing, delaying or reducing the severity of bone cancer, or for preventing and treating bone loss associated with cancer metastases.

EA200970420A 2006-10-27 2007-10-25 APPLICATIONS OF MTKI 1 FOR THE TREATMENT OR PREVENTION OF BONE CANCER EA200970420A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86316706P 2006-10-27 2006-10-27
EP06123060 2006-10-27
US97618807P 2007-09-28 2007-09-28
PCT/EP2007/061501 WO2008049904A2 (en) 2006-10-27 2007-10-25 Use of mtki 1 for treating or preventing bone cancer

Publications (1)

Publication Number Publication Date
EA200970420A1 true EA200970420A1 (en) 2009-12-30

Family

ID=39066650

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970420A EA200970420A1 (en) 2006-10-27 2007-10-25 APPLICATIONS OF MTKI 1 FOR THE TREATMENT OR PREVENTION OF BONE CANCER

Country Status (11)

Country Link
EP (1) EP2101782A2 (en)
JP (1) JP2010507628A (en)
KR (1) KR20090086977A (en)
AU (1) AU2007310845A1 (en)
BR (1) BRPI0718021A2 (en)
CA (1) CA2664165A1 (en)
EA (1) EA200970420A1 (en)
IL (1) IL198344A0 (en)
MX (1) MX2009004438A (en)
NO (1) NO20092059L (en)
WO (1) WO2008049904A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8603801A1 (en) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv DERIVATIVES OF QUINAZOLINE
JO3088B1 (en) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv Macrocyclic Quinazoline derivatives and their use as MTKI
GB0507347D0 (en) * 2005-04-12 2005-05-18 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
MX2009004438A (en) 2009-05-11
AU2007310845A1 (en) 2008-05-02
BRPI0718021A2 (en) 2013-11-12
NO20092059L (en) 2009-06-29
JP2010507628A (en) 2010-03-11
KR20090086977A (en) 2009-08-14
WO2008049904A2 (en) 2008-05-02
IL198344A0 (en) 2010-02-17
EP2101782A2 (en) 2009-09-23
CA2664165A1 (en) 2008-05-02
WO2008049904A3 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
NO20081935L (en) HIV integrase
WO2008079988A3 (en) Quinazolines for pdk1 inhibition
EA200900613A1 (en) SPIROKETONE ACETYL-COA-CARBOXYLAS INHIBITORS
WO2008051416A3 (en) Compounds that inhibit the activity of hsp90 for treating infections
WO2008060767A3 (en) Macrocyclic benzofused pyrimidine derivatives
WO2008118823A3 (en) Compositions and methods for inhibition of the jak pathway
WO2007117607A3 (en) Quinazolines for pdk1 inhibition
MX2009006536A (en) Organic compounds and their uses.
WO2007092622A3 (en) Compositions and methods for treating bone
EA200900802A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DISEASES
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
EA201100874A1 (en) COMPOUNDS FOR CANCER TREATMENT
DK2054418T3 (en) Dihydrothienopyrimidines as AKT protein kinase inhibitors
WO2012068096A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
EA201000895A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIZOSOME DISEASES
WO2008133734A3 (en) Method and compositions for treating hiv infections
WO2008036379A3 (en) Serine hydrolase inhibitors
MX2008015775A (en) Compounds and compositions for treatment of cancer.
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
WO2007112121A3 (en) Tetracycline compounds and methods of treatment
TW200801018A (en) 6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors
EA200800570A1 (en) PHOSPHONIC RIFAMYCINES AND THEIR APPLICATION FOR PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS
EA201170344A1 (en) AZAINDOL IAP INHIBITORS
WO2004075775A3 (en) Treatment of excessive osteolyisis with indolinone compounds